Plain-English translation of NCT06898203 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing a new device called SkinScan3D that uses 3D imaging to measure skin lesions caused by Kaposi Sarcoma. The study compares how well this new device works compared to the current standard method of measuring lesions with a ruler. Researchers hope that SkinScan3D could make it easier and more accurate for doctors to track how your Kaposi Sarcoma is responding to treatment.
Right now, doctors measure Kaposi Sarcoma lesions by hand using a ruler, which can be inconsistent and time-consuming. This trial is trying to see if a new 3D imaging device could provide faster, more accurate, and more reliable measurements to help doctors better track your disease and treatment progress.
You likely qualify if…
You likely don't qualify if…
If you join, researchers will measure three of your Kaposi Sarcoma skin lesions using both the traditional ruler method and the new SkinScan3D device. Depending on which part of the study you enter, you may have lesions measured during your first three months using the standard ruler method, and then switch to the new device for comparison. The study involves visits to your care provider where the measurements will be taken and the new device will be tested in real-world practice settings.
AI-generated summary from trial data · Jul 14, 2026 · Not medical advice
Kenya
Uganda
Sponsor
Washington University School of Medicine
Collaborators
National Cancer Institute (NCI), Pensievision
Enrollment target
~300 participants
Started
April 2026
Primary completion
November 2028
Age range
18 Years and older
Last updated on clinicaltrials.gov in July 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Thomas Odeny, MBChB, MPH, PhD
Washington University School of Medicine
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.